Exact Mass: 285.0965

Exact Mass Matches: 285.0965

Found 14 metabolites which its exact mass value is equals to given mass value 285.0965, within given mass tolerance error 0.001 dalton. Try search metabolite list with more accurate mass tolerance error 0.0002 dalton.

N-Acetylcytidine

N(4)-acetylcytidine

C11H15N3O6 (285.0961)


Cytidine in which one of the exocyclic amino hydrogens is substituted by an acetyl group. N4-Acetylcytidine is an endogenous metabolite. N4-Acetylcytidine is an endogenous metabolite.

   

N4-Acetylcytidine

N-{1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-2-oxo-1,2-dihydropyrimidin-4-yl}acetamide

C11H15N3O6 (285.0961)


N4-Acetylcytidine is a modified nucleoside. N4-acetylcytidine is an endogenous urinary nucleoside product of the degradation of transfer ribonucleic acid (tRNA); urinary nucleosides are biological markers for patients with colorectal cancer. tRNA has been shown to be excreted in abnormal amounts in the urine of cancer patients. tRNA from neoplastic tissue had a much more rapid turnover rate than the tRNA from the corresponding normal tissue. Evidence indicates that methylation of tRNA occurs only after synthesis of the intact macromolecule. Because there are no specific enzyme systems to incorporate the modified nucleosides into the macromolecular nucleic acid, these nucleosides once released in the process of tRNA turnover cannot be reutilized, nor are they further degraded, but are excreted in urine. (PMID: 15991285, 3506820) [HMDB] N4-Acetylcytidine is a modified nucleoside. N4-acetylcytidine is an endogenous urinary nucleoside product of the degradation of transfer ribonucleic acid (tRNA); urinary nucleosides are biological markers for patients with colorectal cancer. tRNA has been shown to be excreted in abnormal amounts in the urine of cancer patients. tRNA from neoplastic tissue had a much more rapid turnover rate than the tRNA from the corresponding normal tissue. Evidence indicates that methylation of tRNA occurs only after synthesis of the intact macromolecule. Because there are no specific enzyme systems to incorporate the modified nucleosides into the macromolecular nucleic acid, these nucleosides once released in the process of tRNA turnover cannot be reutilized, nor are they further degraded, but are excreted in urine. (PMID: 15991285, 3506820). N4-Acetylcytidine is an endogenous metabolite. N4-Acetylcytidine is an endogenous metabolite.

   

4,9-anhydro-11-deoxyTTX

4,9-anhydro-11-deoxyTTX

C11H15N3O6 (285.0961)


   

N4-Acetylcytidine

N4-Acetylcytidine

C11H15N3O6 (285.0961)


CONFIDENCE standard compound; INTERNAL_ID 309

   

4-Acetylcytidine

4-Acetyl-1-(beta-delta-ribofuranosyl)cytosine

C11H15N3O6 (285.0961)


N4-Acetylcytidine is an endogenous metabolite. N4-Acetylcytidine is an endogenous metabolite.

   

1-propenyl-2,3-diMethyliMidazoliuM hexafluorophosphate

1-propenyl-2,3-diMethyliMidazoliuM hexafluorophosphate

C8H16F6N2P (285.0955)


   

L-GAMMA-GLUTAMYL-P-NITROANILIDE MONOHYDRATE

L-GAMMA-GLUTAMYL-P-NITROANILIDE MONOHYDRATE

C11H15N3O6 (285.0961)


   

N-[1-[(2R,3S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidin-4-yl]acetamide

N-[1-[(2R,3S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidin-4-yl]acetamide

C11H15N3O6 (285.0961)


   

1-Butyl-3-[[(4,5-dimethyl-3-thiophenyl)-oxomethyl]amino]thiourea

1-Butyl-3-[[(4,5-dimethyl-3-thiophenyl)-oxomethyl]amino]thiourea

C12H19N3OS2 (285.0969)


   

5-[2-(2,6-Difluorophenyl)ethyl]-8-quinolinol

5-[2-(2,6-Difluorophenyl)ethyl]-8-quinolinol

C17H13F2NO (285.0965)


   

(1R,10S,11R,12R,13S,14R)-3-amino-11-(hydroxymethyl)-6,9-dioxa-2,4-diazapentacyclo[8.3.1.01,7.05,13.08,12]tetradec-3-ene-8,11,14-triol

(1R,10S,11R,12R,13S,14R)-3-amino-11-(hydroxymethyl)-6,9-dioxa-2,4-diazapentacyclo[8.3.1.01,7.05,13.08,12]tetradec-3-ene-8,11,14-triol

C11H15N3O6 (285.0961)


   

PI3K/Akt/mTOR-IN-2

PI3K/Akt/mTOR-IN-2

C17H13F2NO (285.0965)


PI3K/Akt/mTOR-IN-2 is a PI3K/AKT/mTOR pathway inhibitor. PI3K/Akt/mTOR-IN-2 possess anti-cancer effects and selectivity against MDA-MB-231 cells with IC50 value of 2.29 μM. PI3K/Akt/mTOR-IN-2 can induce cancer cell cycle arrest and apoptosis[1].

   

7-imino-2-methyl-10,13,15-trioxa-6,8-diazapentacyclo[7.4.1.1³,¹².0⁵,¹¹.0⁵,¹⁴]pentadecane-2,4,12-triol

7-imino-2-methyl-10,13,15-trioxa-6,8-diazapentacyclo[7.4.1.1³,¹².0⁵,¹¹.0⁵,¹⁴]pentadecane-2,4,12-triol

C11H15N3O6 (285.0961)


   

(1r,2s,3s,4s,5r,9s,11s,12s,14r)-7-imino-2-methyl-10,13,15-trioxa-6,8-diazapentacyclo[7.4.1.1³,¹².0⁵,¹¹.0⁵,¹⁴]pentadecane-2,4,12-triol

(1r,2s,3s,4s,5r,9s,11s,12s,14r)-7-imino-2-methyl-10,13,15-trioxa-6,8-diazapentacyclo[7.4.1.1³,¹².0⁵,¹¹.0⁵,¹⁴]pentadecane-2,4,12-triol

C11H15N3O6 (285.0961)